Search research articles
Contact Us
Filters
Showing results (251-260 of 442) with videos related to
Page
of 45
Sort By:
JCO Precision Oncology
|
September 11, 2020
Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With <i>BRAF</i>-Mutated Malignancies
Vivek Subbiah, Shiraj Sen, Kenneth R Hess, et al.
Molecular Cancer Therapeutics
|
December 15, 2017
Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers
Divya Sakamuri, Isabella C Glitza, Sonia L Betancourt Cuellar, et al.
Plos One
|
March 4, 2014
FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors
Denis L Jardim, Jennifer J Wheler, Kenneth Hess, et al.
Scientific Reports
|
March 13, 2021
Associations between the gut microbiome and fatigue in cancer patients
Joud Hajjar, Tito Mendoza, Liangliang Zhang, et al.
NPJ Precision Oncology
|
March 1, 2026
A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors
Gerald Falchook, Camila Braganca Xavier, David Van Veenhuyzen, et al.
British Journal of Cancer
|
February 21, 2018
Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials
Shiraj Sen, Kenneth Hess, David S Hong, et al.
International Journal of Cancer
|
January 26, 2019
First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors
Ignacio Garrido-Laguna, Ian Krop, Howard A Burris, et al.
Clinical Genitourinary Cancer
|
December 25, 2013
A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma
David S Hong, Michael S Gordon, Wolfram E Samlowski, et al.
Oncotarget
|
June 11, 2014
Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway
Jennifer J Wheler, Stacy L Moulder, Aung Naing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 20, 2023
A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas
Mrinal M Gounder, Todd M Bauer, Gary K Schwartz, et al.
Page
of 45
Search research articles
Search
Showing results (251-260 of 442) with videos related to
Sort By:
Page
of 45
JCO Precision Oncology
|
September 11, 2020
Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With <i>BRAF</i>-Mutated Malignancies
Vivek Subbiah, Shiraj Sen, Kenneth R Hess, et al.
Molecular Cancer Therapeutics
|
December 15, 2017
Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers
Divya Sakamuri, Isabella C Glitza, Sonia L Betancourt Cuellar, et al.
Plos One
|
March 4, 2014
FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors
Denis L Jardim, Jennifer J Wheler, Kenneth Hess, et al.
Scientific Reports
|
March 13, 2021
Associations between the gut microbiome and fatigue in cancer patients
Joud Hajjar, Tito Mendoza, Liangliang Zhang, et al.
NPJ Precision Oncology
|
March 1, 2026
A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors
Gerald Falchook, Camila Braganca Xavier, David Van Veenhuyzen, et al.
British Journal of Cancer
|
February 21, 2018
Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials
Shiraj Sen, Kenneth Hess, David S Hong, et al.
International Journal of Cancer
|
January 26, 2019
First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors
Ignacio Garrido-Laguna, Ian Krop, Howard A Burris, et al.
Clinical Genitourinary Cancer
|
December 25, 2013
A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma
David S Hong, Michael S Gordon, Wolfram E Samlowski, et al.
Oncotarget
|
June 11, 2014
Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway
Jennifer J Wheler, Stacy L Moulder, Aung Naing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 20, 2023
A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas
Mrinal M Gounder, Todd M Bauer, Gary K Schwartz, et al.
Page
of 45